<DOC>
	<DOCNO>NCT01365468</DOCNO>
	<brief_summary>This study evaluate antitumor activity safety RAD001 patient Plexiform neurofibroma ( PN ) associate Neurofibromatosis Type 1 ( NF1 ) . The aim study : 1. determine whether RAD001 , administrate orally daily continuous dose schedule might : 1 . Increases time disease progression ( TTP ) base volumetric MRI measurement child adult NF1 inoperable document progressive PN ( stratum 1 ) . 2 . Results objective radiographic response base volumetric MRI measurement child adult NF1 inoperable PN absence document radiographic progression trail entry ( stratum 2 . To evaluate tolerability toxicity chronic RAD001 administration patient population assess NCI Common Toxicity Criteria , version 4.0 .</brief_summary>
	<brief_title>Efficacy Safety RAD001 Treating Plexiform Neurofibromas ( PN ) Associated With Neurofibromatosis ( NF1 )</brief_title>
	<detailed_description>Approximately 20 patient enrol receive everolimus open label manner . A total 9 patient enrol either Stratum 1 Stratum 2 . The study open enrollment 2 year . Because target enrollment achieve period , study terminate less patient plan .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma , Plexiform</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Clinically definite diagnosis NF1 accord NIH consensus conference criterion . 2 . Patients must PN potential cause significant morbidity , lesion could compromise airway great vessel , lesion could cause nerve compression , lesion could result major deformity significant cosmetic problem 3 . Measurable disease : patient must least one measurable PN amenable volumetric MRI analysis . 1 . Chronic treatment systemic steroid another immunosuppressive agent . 2 . Evidence active optic glioma , malignant glioma , malignant peripheral nerve sheath tumor , cancer require treatment chemotherapy radiation therapy . 3 . Clinical evidence significantly impaired lung function 4 . Pregnancy breast feed . 5 . Prior therapy mTOR inhibitor ( e.g.sirolimus , temsirolimus , everolimus ) . 6 . No contraindication MRI assessments Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>RAD001 ,</keyword>
	<keyword>Everolimus ,</keyword>
	<keyword>Plexiform Neurofibroma ,</keyword>
	<keyword>Neurofibromatosis Type 1</keyword>
</DOC>